• Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) experienced a dramatic drop of approximately 49.5%, with its stock price falling to $1.01.
• Vor Biopharma Inc. (NASDAQ:VOR) saw its stock price decrease by 47.77% to $9.82, following a significant market correction.

In the recent market downturn, several companies have experienced significant price declines, reflecting various underlying challenges and market sentiments. Among the top losers, Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) saw a dramatic drop of approximately 49.5%, with its price falling to $1.01. This biotechnology firm, focused on developing cancer treatments, has faced volatility, with its stock price fluctuating from a high of $88 to a low of $0.91 over the past year. Salarius recently announced a public offering to raise approximately $7 million, which includes over 2.5 million shares of common stock and pre-funded warrants for an additional 2.1 million shares. This move aims to bolster its financial position amidst market challenges.

Vor Biopharma Inc. (NASDAQ:VOR), engaged in developing treatments for cancer patients, saw its stock price halve, decreasing by 47.77% to $9.82. The company, which has been working on engineered hematopoietic stem cell therapies, has experienced a significant market correction from its yearly high of $65.8. Despite this, Vor Biopharma has successfully secured a $100 million offering following positive results from a kidney disease trial, pricing 10 million shares at $10 each in this underwritten public offering.

Outset Medical, Inc. (NASDAQ:OM), a medical technology company that develops innovative hemodialysis systems, witnessed a 46.89% decline in its stock price to $6.40. This decrease reflects broader challenges within the healthcare sector, particularly for companies in the medical device industry. The pre-market session saw declines in major stocks, including Outset Medical, as highlighted by the S&P 500 futures' decrease of around 0.2%.

Epsium Enterprise Limited (EPSM), which engages in the import trading and wholesale of alcoholic beverages, saw its stock price decrease by 43.1% to $3.27. The company, with a diverse portfolio of wines and spirits, has faced market adjustments, with its stock price ranging from a high of $155 to a low of $2.62 over the past year. Epsium has responded to unusual trading activity in its shares by issuing a statement addressing this recent market behavior.

These significant price movements highlight the volatility and challenges faced by companies across various sectors. Market participants will closely monitor these companies for any signs of recovery or further adjustments in their stock prices.